View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsSynairgen 将来の成長Future 基準チェック /06現在、 Synairgenの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長23.2%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Dec 10Synairgen Limited Announces First Patient Dosed in the Global Phase 2 Invent Clinical StudySynairgen announced that the first participant has been dosed in the global phase 2 INVENT clinical study, which is designed to evaluate the efficacy and safety of SNG001 (inhaled interferon-beta) in mechanically-ventilated patients infected with a range of respiratory viruses. SNG001 is a broadly-acting anti-viral which is targeted to the lungs using a specific nebuliser technology enabled by the Company's partnership with Aerogen. INVENT is a large clinical study which is being progressed in intensive care units of specialised clinical centres in US, UK and selected European countries. It follows a randomised, placebo-controlled, double-blind design and aims to enrol 550 patients, with a protocol-defined interim analysis scheduled during 2026. The primary endpoint is 28-day all-cause mortality, whilst secondary endpoints include duration of mechanical ventilation and of ICU stay, as well as viral load in lung-derived samples.Board Change • Mar 20Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director Martin Murphy was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Jan 16+ 1 more updateSynairgen plc Announces the Appointment of Martin Murphy to the Board as an Independent Non-Executive Director and Chair of the Remuneration CommitteeSynairgen plc announced the appointment of Martin Murphy to the Board as an independent Non-Executive Director and Chair of the Remuneration Committee, effective immediately. Martin Murphy is a seasoned healthcare veteran with over 25 years of leadership experience in life sciences investment. Previously, Martin Murphy was co-founder of Syncona Limited, a FTSE 250 healthcare investment company, and CEO and Investment Committee Chair of Syncona Investment Management Limited. He now holds various Chair positions and is a Director and founding investor of NASDAQ-listed Autolus Therapeutics plc. Between 2005-2012, he served as a Managing Director of MVM Life Science Partners LLP. Martin holds a PhD from the University of Cambridge and an MA in Biochemistry from the University of Oxford.お知らせ • Sep 18+ 1 more updateSynairgen plc, Annual General Meeting, Oct 10, 2024Synairgen plc, Annual General Meeting, Oct 10, 2024. Location: numis, 9th floor, 45 gresham street, ec2v 7bf, london United Kingdomお知らせ • Sep 05Synairgen plc Announces Stepping Down of Phillip Monk from the Board, Effective December 31, 2024Synairgen plc announced that, following 18 years of service, Dr. Phillip Monk is stepping down from the Board and will leave the Company on December 31, 2024. With Synairgen's resources dedicated to the clinical development of SNG001, Dr. Marcin Mankowski became the Company's Chief Medical Officer in 2023 and will continue to lead the clinical development strategy for SNG001. The Company looks forward to announcing further Board changes ahead of hosting its Annual General Meeting in early October.New Risk • Apr 08New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 37% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€11.5m market cap, or US$12.4m).Board Change • Mar 25Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Non-Executive Director Amanda Radford was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Dec 20Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Non-Executive Director Amanda Radford was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Oct 11+ 1 more updateSynairgen plc Announces Executive ChangesSynairgen plc announced that Joseph Colliver has been appointed chief financial officer (CFO) with effect from 6 November 2023. In conjunction with this appointment and following nearly 20 years of loyal service and an orderly handover, John Ward will step down from the role of CFO on 3 November. Joseph Colliver has significant financial leadership experience, including most recently as CFO and non-executive director of several listed life sciences companies. He has previously held CFO and senior commercial roles within the Kantar division of WPP PLC. He also has many years of experience as a consultant and in various Board roles, with a deep understanding of the strategy, governance and regulatory requirements of biotechnology companies. Full name: Joseph Tregonning Colliver; Age: 43. Current directorships: Phytome Life Sciences Plc; Phytome Research Ltd; Hellenic Dynamics Plc; Psych Capital Plc; Colliver Advisory Ltd. Historic directorships in previous 5 years: Sativa Wellness Group Inc; Borganic Consulting Inc; Olimax NT Sp z o.o; Sativa Group Ltd; Blood Matters Ltd; Sativa Cultivation and Extraction Limited; Sativa Wellness Ltd; Phytovista Laboratories Ltd; Goodbody Botanicals Ltd; Tessellate Collective Ltd; Goodbody and Blunt Ltd; Sativa Investments Ltd; Goodbody Wellness Limited; George Botanicals Ltd; Sativa Cosmetics Ltd.お知らせ • Oct 05Synairgen plc Announces Appointment of Dr. Marcin Mankowski as Chief Medical OfficerSynairgen plc announces the appointment of Dr. Marcin Mankowski as Chief Medical Officer (CMO), effective immediately. Marcin is a seasoned pharmaceutical physician and drug developer with more than 27 years of pharmaceutical industry experience and a strong background in infectious diseases and respiratory medicine. Marcin joins Synairgen on a full-time basis having worked with the Company as acting CMO and a clinical trials consultant since 2018. Prior to joining Synairgen, Marcin was Co-Founder and Chief Executive Officer at tranScrip Ltd, a leading contract drug development business, where he played an integral strategic role in both driving investment as well as leading a vast range of projects across all stages of drug development and multiple therapy areas.Board Change • Aug 11Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Non-Executive Director Amanda Radford was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Jun 02Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Non-Executive Director Amanda Radford was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • May 25Synairgen plc, Annual General Meeting, Jun 29, 2023Synairgen plc, Annual General Meeting, Jun 29, 2023, at 09:00 Coordinated Universal Time. Location: Numis, 45 Gresham Street, London EC2V 7BF London United KingdomBoard Change • Jan 13Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Non-Executive Director Amanda Radford was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Apr 27Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 2 experienced directors. 7 highly experienced directors. 1 independent director (7 non-independent directors). Independent Non-Executive Director Theo Harold was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Mar 18Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 2 experienced directors. 7 highly experienced directors. 1 independent director (7 non-independent directors). Independent Non-Executive Director Theo Harold was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Feb 22Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 2 experienced directors. 7 highly experienced directors. 1 independent director (7 non-independent directors). Independent Non-Executive Director Theo Harold was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Jan 11Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 2 experienced directors. 7 highly experienced directors. 1 independent director (7 non-independent directors). Independent Non-Executive Director Theo Harold was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Nov 15Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 5 experienced directors. 4 highly experienced directors. 1 independent director (7 non-independent directors). Independent Non-Executive Director Theo Harold was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Oct 01No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 4 highly experienced directors. No independent directors (7 non-independent directors). Non-Executive Director & Member of Scientific Advisory Board Iain Peter Buchanan was the last director to join the board, commencing their role in 2010. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Is New 90 Day High Low • Feb 13New 90-day high: €2.14The company is up 43% from its price of €1.50 on 13 November 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €14.10 per share.Is New 90 Day High Low • Jan 27New 90-day high: €2.08The company is up 14% from its price of €1.83 on 28 October 2020. The German market is up 16% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €13.45 per share. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Synairgen は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測BST:OMY - アナリストの将来予測と過去の財務データ ( )GBP Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/2024N/A-7-7-7N/A3/31/2024N/A-8-7-7N/A12/31/2023N/A-8-8-8N/A9/30/2023N/A-9-6-6N/A6/30/2023N/A-10-4-4N/A3/31/2023N/A-14-9-9N/A12/31/2022N/A-18-14-14N/A9/30/2022N/A-23-21-21N/A6/30/2022N/A-28-28-28N/A3/31/2022N/A-38-35-35N/A12/31/2021N/A-49-41-41N/A9/30/2021N/A-46-44-44N/A6/30/2021N/A-43-48-48N/A3/31/2021N/A-28-36-36N/A12/31/2020N/A-14-24-24N/A9/30/2020N/A-10-15-15N/A6/30/2020N/A-6-6-6N/A3/31/2020N/A-5-4-4N/A12/31/2019N/A-4-3-3N/A9/30/20190-4-4-4N/A6/30/20190-4-4-4N/A3/31/20190-3-4-4N/A12/31/20180-3-4-4N/A9/30/20183-1-1-1N/A6/30/20185222N/A3/31/201852N/A2N/A12/31/201752N/A2N/A9/30/201730N/A-1N/A6/30/20170-3N/A-3N/A3/31/20170-3N/A-3N/A12/31/2016N/A-3N/A-3N/A9/30/2016N/A-3N/A-3N/A6/30/2016N/A-3N/A-2N/A3/31/20160-2N/A-2N/A12/31/20150-2N/A-2N/A9/30/20150-2N/A-2N/A6/30/20150-2N/A-2N/A3/31/201520N/A0N/A12/31/201441N/A2N/A9/30/201441N/A2N/A6/30/201441N/A3N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: OMYの予測収益成長が 貯蓄率 ( 1.3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: OMYの収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: OMYの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: OMYの収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: OMYの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: OMYの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/06/15 02:17終値2025/03/18 00:00収益2024/06/30年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Synairgen plc 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関null nullCavendishMark BrewerCavendish
お知らせ • Dec 10Synairgen Limited Announces First Patient Dosed in the Global Phase 2 Invent Clinical StudySynairgen announced that the first participant has been dosed in the global phase 2 INVENT clinical study, which is designed to evaluate the efficacy and safety of SNG001 (inhaled interferon-beta) in mechanically-ventilated patients infected with a range of respiratory viruses. SNG001 is a broadly-acting anti-viral which is targeted to the lungs using a specific nebuliser technology enabled by the Company's partnership with Aerogen. INVENT is a large clinical study which is being progressed in intensive care units of specialised clinical centres in US, UK and selected European countries. It follows a randomised, placebo-controlled, double-blind design and aims to enrol 550 patients, with a protocol-defined interim analysis scheduled during 2026. The primary endpoint is 28-day all-cause mortality, whilst secondary endpoints include duration of mechanical ventilation and of ICU stay, as well as viral load in lung-derived samples.
Board Change • Mar 20Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director Martin Murphy was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jan 16+ 1 more updateSynairgen plc Announces the Appointment of Martin Murphy to the Board as an Independent Non-Executive Director and Chair of the Remuneration CommitteeSynairgen plc announced the appointment of Martin Murphy to the Board as an independent Non-Executive Director and Chair of the Remuneration Committee, effective immediately. Martin Murphy is a seasoned healthcare veteran with over 25 years of leadership experience in life sciences investment. Previously, Martin Murphy was co-founder of Syncona Limited, a FTSE 250 healthcare investment company, and CEO and Investment Committee Chair of Syncona Investment Management Limited. He now holds various Chair positions and is a Director and founding investor of NASDAQ-listed Autolus Therapeutics plc. Between 2005-2012, he served as a Managing Director of MVM Life Science Partners LLP. Martin holds a PhD from the University of Cambridge and an MA in Biochemistry from the University of Oxford.
お知らせ • Sep 18+ 1 more updateSynairgen plc, Annual General Meeting, Oct 10, 2024Synairgen plc, Annual General Meeting, Oct 10, 2024. Location: numis, 9th floor, 45 gresham street, ec2v 7bf, london United Kingdom
お知らせ • Sep 05Synairgen plc Announces Stepping Down of Phillip Monk from the Board, Effective December 31, 2024Synairgen plc announced that, following 18 years of service, Dr. Phillip Monk is stepping down from the Board and will leave the Company on December 31, 2024. With Synairgen's resources dedicated to the clinical development of SNG001, Dr. Marcin Mankowski became the Company's Chief Medical Officer in 2023 and will continue to lead the clinical development strategy for SNG001. The Company looks forward to announcing further Board changes ahead of hosting its Annual General Meeting in early October.
New Risk • Apr 08New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 37% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€11.5m market cap, or US$12.4m).
Board Change • Mar 25Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Non-Executive Director Amanda Radford was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Dec 20Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Non-Executive Director Amanda Radford was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 11+ 1 more updateSynairgen plc Announces Executive ChangesSynairgen plc announced that Joseph Colliver has been appointed chief financial officer (CFO) with effect from 6 November 2023. In conjunction with this appointment and following nearly 20 years of loyal service and an orderly handover, John Ward will step down from the role of CFO on 3 November. Joseph Colliver has significant financial leadership experience, including most recently as CFO and non-executive director of several listed life sciences companies. He has previously held CFO and senior commercial roles within the Kantar division of WPP PLC. He also has many years of experience as a consultant and in various Board roles, with a deep understanding of the strategy, governance and regulatory requirements of biotechnology companies. Full name: Joseph Tregonning Colliver; Age: 43. Current directorships: Phytome Life Sciences Plc; Phytome Research Ltd; Hellenic Dynamics Plc; Psych Capital Plc; Colliver Advisory Ltd. Historic directorships in previous 5 years: Sativa Wellness Group Inc; Borganic Consulting Inc; Olimax NT Sp z o.o; Sativa Group Ltd; Blood Matters Ltd; Sativa Cultivation and Extraction Limited; Sativa Wellness Ltd; Phytovista Laboratories Ltd; Goodbody Botanicals Ltd; Tessellate Collective Ltd; Goodbody and Blunt Ltd; Sativa Investments Ltd; Goodbody Wellness Limited; George Botanicals Ltd; Sativa Cosmetics Ltd.
お知らせ • Oct 05Synairgen plc Announces Appointment of Dr. Marcin Mankowski as Chief Medical OfficerSynairgen plc announces the appointment of Dr. Marcin Mankowski as Chief Medical Officer (CMO), effective immediately. Marcin is a seasoned pharmaceutical physician and drug developer with more than 27 years of pharmaceutical industry experience and a strong background in infectious diseases and respiratory medicine. Marcin joins Synairgen on a full-time basis having worked with the Company as acting CMO and a clinical trials consultant since 2018. Prior to joining Synairgen, Marcin was Co-Founder and Chief Executive Officer at tranScrip Ltd, a leading contract drug development business, where he played an integral strategic role in both driving investment as well as leading a vast range of projects across all stages of drug development and multiple therapy areas.
Board Change • Aug 11Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Non-Executive Director Amanda Radford was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Jun 02Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Non-Executive Director Amanda Radford was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • May 25Synairgen plc, Annual General Meeting, Jun 29, 2023Synairgen plc, Annual General Meeting, Jun 29, 2023, at 09:00 Coordinated Universal Time. Location: Numis, 45 Gresham Street, London EC2V 7BF London United Kingdom
Board Change • Jan 13Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Non-Executive Director Amanda Radford was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Apr 27Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 2 experienced directors. 7 highly experienced directors. 1 independent director (7 non-independent directors). Independent Non-Executive Director Theo Harold was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Mar 18Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 2 experienced directors. 7 highly experienced directors. 1 independent director (7 non-independent directors). Independent Non-Executive Director Theo Harold was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Feb 22Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 2 experienced directors. 7 highly experienced directors. 1 independent director (7 non-independent directors). Independent Non-Executive Director Theo Harold was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Jan 11Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 2 experienced directors. 7 highly experienced directors. 1 independent director (7 non-independent directors). Independent Non-Executive Director Theo Harold was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Nov 15Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 5 experienced directors. 4 highly experienced directors. 1 independent director (7 non-independent directors). Independent Non-Executive Director Theo Harold was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Oct 01No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 4 highly experienced directors. No independent directors (7 non-independent directors). Non-Executive Director & Member of Scientific Advisory Board Iain Peter Buchanan was the last director to join the board, commencing their role in 2010. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Is New 90 Day High Low • Feb 13New 90-day high: €2.14The company is up 43% from its price of €1.50 on 13 November 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €14.10 per share.
Is New 90 Day High Low • Jan 27New 90-day high: €2.08The company is up 14% from its price of €1.83 on 28 October 2020. The German market is up 16% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €13.45 per share.